Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $47 from $44 and keeps a Buy rating on the shares. The firm says the company “continues to march forward with discipline” towards the August 8 FDA action date for LNZ100 in aceclidine eyedrop for presbyopia. Citi continues to forecast high likelihood of approval. The “recent and uneventful” mid-cycle review in further notched up the firm’s conviction, driving the target higher, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid FDA Progress and Commercial Readiness
- Buy Rating for LENZ Therapeutics Driven by Promising LNZ100 Eye Drop Prospects
- Lenz Therapeutics reports Q4 EPS (46c), consensus (40c)
- Closing Bell Movers: Harrow spikes 24% on revenue beat, leverage update
- Lenz Therapeutics initiated with a Buy at TD Cowen